April 15, 2025
Article
Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.
February 20, 2025
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.
February 19, 2025
Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.
February 18, 2025
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.
Optune Lua Receives CE Mark in Europe for Metastatic NSCLC
How to Best Navigate a Diagnosis of Lung and Head and Neck Cancer
Joy Anderson Reflects on Her Diagnosis of a Rare Blood Cancer
The Burst of Spring: Reflection for Those Living with Cancer